In this podcast, Drs Jeffrey Swigris and Toby Maher discuss the future of idiopathic pulmonary fibrosis. Find out where we're headed regarding diagnostic and treatment innovations on the near horizon.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982426). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Idiopathic Pulmonary Fibrosis: Present Understanding and Future Options https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584113/

Predicting Prognosis in Idiopathic Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/21319590/

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis https://pubmed.ncbi.nlm.nih.gov/35569036/

Inhaled Treprostinil and Forced Vital Capacity in Patients With Interstitial Lung Disease and Associated Pulmonary Hypertension: A Post-hoc Analysis of the INCREASE Study https://pubmed.ncbi.nlm.nih.gov/34214475/

Pulmonary Fibrosis Foundation https://www.pulmonaryfibrosis.org/

Predictors of Progression in Systemic Sclerosis Patients With Interstitial Lung Disease https://pubmed.ncbi.nlm.nih.gov/32079645/